Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB11 | O95342 | 2/20 | 0.48 |
| ▸ | CCR2 | P41597 | 9/20 | 0.43 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.39 |
| ▸ | EDNRB | P24530 | 2/20 | 0.39 |
| ▸ | EDNRA | P25101 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6595115 | 0.88 | ABCB11 (0.55) | ABCB11CCR2EDNRBEDNRA | |
| SCHEMBL7087364 | 0.88 | ABCB11 (0.52) | ABCB11CCR2PTGDR2TP53 | |
| SCHEMBL7592632 | 0.75 | ABCB11 (0.41) | ABCB11CCR2MAPTLMNAMEN1 | |
| SCHEMBL7083775 | 0.74 | ABCB11 (0.78) | ABCB11CCR2MAPTLMNAMEN1 | |
| SCHEMBL7086770 | 0.74 | ABCB11 (0.48) | ABCB11CCR2MAPTLMNAHTT | |
| SCHEMBL6780182 | 0.71 | ABCB11 (0.66) | ABCB11CCR2 | |
| SCHEMBL6780034 | 0.70 | CCR2 (0.61) | ABCB11CCR2EDNRBEDNRAMAPT | |
| SCHEMBL7084277 | 0.69 | ABCB11 (0.63) | ABCB11CCR2PTGER1 | |
| SCHEMBL7088263 | 0.68 | ABCB11 (0.44) | ABCB11CCR2MAPTLMNAMEN1 | |
| SCHEMBL7592778 | 0.68 | ABCB11 (0.61) | ABCB11CCR2MAPTLMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030144339-A1 | Indole derivatives as mcp-1 receptor antagonists | ASTRAZENECA AB (SE) | 2003-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144339-A1 | Indole derivatives as mcp-1 receptor antagonists | CCR2, CCR1, CCR5 | ABCB11 391/4885CCR2 1/4885PTGDR2 455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.